Trial Profile
B7-H4 Expression as a predictive biomarker to evaluate response to Nivolumab treatment in patients with non-small cell lung cancer: A Retrospective Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 08 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer